{
  "model": "gemini-2.5-pro",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "workspacePath": "workspaces/gemini-2-5-pro-tumor-vaccine-ici-run-3",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 100775,
  "agentCostUsd": 0.08752337500000001,
  "graderCostUsd": 0,
  "totalCostUsd": 0.08752337500000001,
  "agentUsage": {
    "promptTokens": 36199,
    "cachedTokens": 11107,
    "responseTokens": 2725,
    "thinkingTokens": 2752,
    "totalTokens": 41676
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 36199,
    "cachedTokens": 11107,
    "responseTokens": 2725,
    "thinkingTokens": 2752,
    "totalTokens": 41676
  },
  "modelVersions": [
    "gemini-2.5-pro"
  ],
  "agentFinalText": "- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "datasets_or_cohorts.2.description: Too small: expected string to have >=20 characters",
        "datasets_or_cohorts.3.description: Too small: expected string to have >=20 characters"
      ],
      "content": "{\n    \"paper\": {\n        \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n        \"doi\": \"10.1038/s41586-025-09006-8\",\n        \"publication_year\": 2025,\n        \"domain\": \"oncology-immunology\",\n        \"study_type\": \"preclinical+retrospective\"\n    },\n    \"core_question\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n    \"datasets_or_cohorts\": [\n        {\n            \"id\": \"mouse-efficacy-cohort\",\n            \"label\": \"Mouse efficacy cohort (combination therapy)\",\n            \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n            \"description\": \"78 tumor-bearing mice pooled across repeat experiments.\"\n        },\n        {\n            \"id\": \"mouse-control-cohort\",\n            \"label\": \"Mouse control cohort (vaccine only, ICI only, and vehicle)\",\n            \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n            \"description\": \"84 tumor-bearing mice pooled across matched controls.\"\n        },\n        {\n            \"id\": \"human-retrospective-metastatic-cohort\",\n            \"label\": \"Human retrospective metastatic cohort\",\n            \"sample_size_or_observations\": \"130 patients total\",\n            \"description\": \"130 patients total.\"\n        },\n        {\n            \"id\": \"human-vaccinated-subgroup\",\n            \"label\": \"Human vaccinated subgroup\",\n            \"sample_size_or_observations\": \"43 patients\",\n            \"description\": \"43 patients.\"\n        }\n    ],\n    \"major_limitations\": [\n        \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n        \"Vaccination timing relative to ICI initiation varied across patients.\",\n        \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n        \"Mouse model effects may not map one-to-one to all human tumors.\"\n    ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n    \"findings\": [\n        {\n            \"id\": \"Q01\",\n            \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n            \"value\": \"62.3%\",\n            \"comparator_or_baseline\": \"37.3%\",\n            \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n            \"evidence_line_refs\": [\"L28\"]\n        },\n        {\n            \"id\": \"Q02\",\n            \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n            \"value\": \"40.6%\",\n            \"comparator_or_baseline\": \"20.6%\",\n            \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n            \"evidence_line_refs\": [\"L29\"]\n        },\n        {\n            \"id\": \"Q03\",\n            \"metric\": \"Retrospective human survival comparison p-value\",\n            \"value\": \"p=0.01\",\n            \"comparator_or_baseline\": \"N/A\",\n            \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n            \"evidence_line_refs\": [\"L30\"]\n        },\n        {\n            \"id\": \"Q04\",\n            \"metric\": \"Type I interferon response score (normalized units)\",\n            \"value\": \"3.1\",\n            \"comparator_or_baseline\": \"1.0\",\n            \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n            \"evidence_line_refs\": [\"L31\"]\n        },\n        {\n            \"id\": \"Q05\",\n            \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n            \"value\": \"2.4x\",\n            \"comparator_or_baseline\": \"1.0x\",\n            \"interpretation\": \"Checkpoint axis became more targetable\",\n            \"evidence_line_refs\": [\"L32\"]\n        },\n        {\n            \"id\": \"Q06\",\n            \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n            \"value\": \"1.8x\",\n            \"comparator_or_baseline\": \"1.0x\",\n            \"interpretation\": \"Increased immune infiltration with combination therapy\",\n            \"evidence_line_refs\": [\"L33\"]\n        }\n    ],\n    \"controls_or_null_results\": [\n        {\n            \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n            \"evidence_line_ref\": \"L36\"\n        },\n        {\n            \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n            \"evidence_line_ref\": \"L37\"\n        },\n        {\n            \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n            \"evidence_line_ref\": \"L38\"\n        },\n        {\n            \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n            \"evidence_line_ref\": \"L39\"\n        }\n    ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n    \"claims\": [\n        {\n            \"claim_id\": \"C01\",\n            \"claim\": \"Intratumoral mRNA vaccination enhances the diversity of antigens presented on tumor cells.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%\",\n                    \"line_ref\": \"L28\"\n                },\n                {\n                    \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\",\n                    \"line_ref\": \"L29\"\n                }\n            ],\n            \"caveat\": \"The effect is demonstrated in mouse models and the breadth of applicability to human tumors is not fully established.\"\n        },\n        {\n            \"claim_id\": \"C02\",\n            \"claim\": \"mRNA vaccination in tumors induces a type I interferon response, a key step in immune activation.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0\",\n                    \"line_ref\": \"L31\"\n                },\n                {\n                    \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n                    \"line_ref\": \"L42\"\n                }\n            ],\n            \"caveat\": \"The magnitude of the interferon response may vary between different tumor types and microenvironments.\"\n        },\n        {\n            \"claim_id\": \"C03\",\n            \"claim\": \"The combination of intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in preclinical models.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x\",\n                    \"line_ref\": \"L33\"\n                },\n                {\n                    \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n                    \"line_ref\": \"L46\"\n                }\n            ],\n            \"caveat\": \"These are preclinical results in mice, and may not directly translate to human clinical outcomes.\"\n        },\n        {\n            \"claim_id\": \"C04\",\n            \"claim\": \"Prior mRNA vaccination is associated with improved survival in metastatic patients treated with ICIs.\",\n            \"strength\": \"tentative\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A\",\n                    \"line_ref\": \"L30\"\n                },\n                {\n                    \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n                    \"line_ref\": \"L49\"\n                }\n            ],\n            \"caveat\": \"This is a retrospective, non-randomized analysis, so the association may be due to confounding variables rather than a causal effect of the vaccine.\"\n        }\n    ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "glossary.3.definition: Too small: expected string to have >=20 characters"
      ],
      "content": "{\n    \"headline\": \"Injecting tumors with mRNA vaccines could make them more susceptible to cancer immunotherapy.\",\n    \"plain_language_summary\": \"Cancer immunotherapy, which helps the body's own immune system fight cancer, doesn't work for all patients. This study investigated a new strategy to make immunotherapy more effective. Researchers injected mRNA vaccines directly into tumors in mice, which triggered an immune response and made the tumors more sensitive to a type of immunotherapy called immune checkpoint blockade. A retrospective study of human patients also suggested that those who had received an mRNA vaccine for COVID-19 and were also being treated with immunotherapy for metastatic cancer had better survival rates. While these findings are promising, the human study was not a controlled clinical trial, so more research is needed to confirm if this is a true cause-and-effect relationship and a safe and effective treatment strategy for people with cancer.\",\n    \"what_is_new\": [\n        \"Directly injecting an mRNA vaccine into a tumor can trigger a strong local immune response.\",\n        \"This immune response can make tumors that were previously resistant to immunotherapy become sensitive to it.\",\n        \"The study provides a scientific rationale for combining intratumoral mRNA vaccination with immune checkpoint inhibitors.\"\n    ],\n    \"why_caution_is_needed\": [\n        \"The main findings are from mouse studies, which may not translate directly to humans.\",\n        \"The human data is from a retrospective study, not a randomized clinical trial, so it's not possible to draw firm conclusions about cause and effect.\",\n        \"The timing and type of mRNA vaccine might be important factors that need more investigation.\",\n        \"The study was on a mix of cancer types, so it's not clear which specific cancers might benefit most from this approach.\"\n    ],\n    \"glossary\": [\n        {\n            \"term\": \"Immunotherapy\",\n            \"definition\": \"A type of cancer treatment that helps your immune system fight cancer.\"\n        },\n        {\n            \"term\": \"Immune checkpoint inhibitors (ICIs)\",\n            \"definition\": \"A type of immunotherapy that blocks proteins called checkpoints that can stop the immune system from attacking cancer cells.\"\n        },\n        {\n            \"term\": \"mRNA vaccine\",\n            \"definition\": \"A type of vaccine that uses a molecule called messenger RNA (mRNA) to teach your cells how to make a protein that triggers an immune response.\"\n        },\n        {\n            \"term\": \"Intratumoral\",\n            \"definition\": \"Within a tumor.\"\n        }\n    ],\n    \"open_questions\": [\n        \"Which types of cancer are most likely to respond to this combination therapy?\",\n        \"What is the optimal timing and dosage for the intratumoral mRNA vaccine?\",\n        \"Are there any long-term side effects of this treatment?\"\n    ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:43:54.238Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:44:00.860Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:44:30.281Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:44:30.282Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:44:30.282Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:44:30.282Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:44:30.282Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:44:41.241Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:45:01.336Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:45:13.099Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:45:25.816Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
